Search results for "MELLITUS"

showing 10 items of 2089 documents

A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.

2020

The rising prevalence of the metabolic syndrome has led to an increase of non-alcoholic fatty liver disease (NAFLD), and its progressive-inflammatory form called non-alcoholic steatohepatitis (NASH). In recent years, NAFLD and NASH have become major risk factors for developing liver cirrhosis and hepatocellular carcinoma (HCC). In this case, we report a 46-year-old patient with type 2 diabetes mellitus and metabolic comorbidities including obesity and arterial hypertension, who was referred because of rising liver enzymes. After clinical and diagnostic evaluation, the patient was diagnosed with NASH-associated liver cirrhosis, Child-Pugh stage B. A normal blood sugar level was difficult to …

medicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentComorbidityLiver transplantationChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineFatal OutcomeNon-alcoholic Fatty Liver DiseaseDiabetes mellitusInternal medicinemedicineHumans030212 general & internal medicineObesityMetabolic Syndromebusiness.industryFatty liverLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesDiabetes Mellitus Type 2Hepatocellular carcinomaHypertension030211 gastroenterology & hepatologyMetabolic syndromeSteatohepatitisInsulin ResistancebusinessZeitschrift fur Gastroenterologie
researchProduct

Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis

2020

Background Diabetes mellitus may lead to increased serum ammonia and systemic inflammation thereby promoting hepatic encephalopathy (HE). Aim To investigate the potential association between diabetes mellitus/glycaemic control and the presence of covert HE as well as the development of overt HE in a prospective setting. Methods A total of 240 patients with liver cirrhosis were included into this prospective cohort study and followed for a median of 17 months. Covert HE was diagnosed by pathological results in the Portosystemic Hepatic Encephalopathy Score. Predictors for the presence of covert HE or the development of overt HE were analysed using logistic regression or Cox-regression models…

medicine.medical_specialtyCirrhosisHepatologybusiness.industryGastroenterologymedicine.diseaseLogistic regressionGastroenterologyInternal medicineDiabetes mellitusmedicinePharmacology (medical)Liver functionProspective cohort studybusinessComplicationPathologicalHepatic encephalopathyAlimentary Pharmacology & Therapeutics
researchProduct

Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation

2019

Background & Aims Chronic liver disease has negative effects on health-related quality of life (HRQL). We analyzed data from the European non-alcoholic fatty liver disease (NAFLD) registry to assess the effects of NAFLD on HRQL. Methods We collected data from 304 patients (mean age, 52.3 ± 12.9 years) with histologically defined NAFLD enrolled prospectively into the European NAFLD Registry in Germany, the United Kingdom, and Spain. The chronic liver disease questionnaire (CLDQ) was completed within 6 months of liver biopsy collection. Results The mean CLDQ overall score was 5.0 ± 1.2, with the lowest score in the category fatigue (4.3 ± 1.6) and the highest scores for activity (5.4 ± 1.4). …

medicine.medical_specialtyCirrhosisHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologymedicine.diseaseChronic liver diseaseGastroenterology3. Good health03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisDiabetes mellitusLiver biopsyInternal medicineNonalcoholic fatty liver diseasemedicine030211 gastroenterology & hepatologyPatient-reported outcomebusinessBody mass indexClinical Gastroenterology and Hepatology
researchProduct

Role of the receptor tyrosine kinase MER in the development of fibrosis in NAFLD

2015

s / Digestive and Liver Disease 47S (2015) e221–e225 e225 age of these patients was 61 years (SD 12); 53% were female. Compared to HCV patients without steatosis (3347), in patients with steatosis: BMI was ≥25 in 44% vs. 36% (p<0.05) and ≥30 in 18% vs 11% (p=0.05); F4/cirrhosis was present in 28% vs. 32% (p=ns). Among HCV patients with and without steatosis, similar distribution of HCV genotypes, transaminases and gamma GT levels, lipid pattern and other comorbidities were observed. Of 1295 patients with steatosis, in 167 (1.3%) liver biopsy was available and confirmed the NAFLD diagnosis. In this last group of patients the prevalence of diabetes and of cardiovascular disease were higher co…

medicine.medical_specialtyCirrhosisHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyDiseasemedicine.diseaseGastroenterologyLiver diseaseEndocrinologyFibrosisInternal medicineLiver biopsyDiabetes mellitusCohortmedicineSteatosisbusinessDigestive and Liver Disease
researchProduct

Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study

2018

BACKGROUND Cirrhosis is associated with morpho-functional cardiovascular alterations. AIMS To detect early features of cardiovascular damage in HCV-compensated cirrhotic patients using myocardial deformation indices and carotid arterial stiffness, and, further, to evaluate their short-term behaviour after HCV eradication with direct antiviral agents (DAAs). METHODS Thirty-nine consecutive patients with HCV cirrhosis, without previous cardiovascular events, were studied and matched for age, gender and cardiovascular risk factors to 39 controls without liver or cardiovascular disease. Patients and controls underwent a baseline echocardiographic evaluation including global longitudinal strain …

medicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaHepatologybusiness.industryGastroenterologyHepatitis C030204 cardiovascular system & hematologycardiovascular damage cirrhosis HCV global longitudinal strainmedicine.disease03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineDiabetes mellitusArterial stiffnessCardiologyMedicine030211 gastroenterology & hepatologyPharmacology (medical)businessProspective cohort studyPulse wave velocitySubclinical infection
researchProduct

Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany

2018

BACKGROUND Advanced fibrosis has been established as the most important predictor of overall mortality in patients with non-alcoholic fatty liver disease (NAFLD). In contrast to cirrhosis, advanced, non-cirrhotic NAFLD is difficult to identify and data from Germany are lacking. AIM To identify clinical factors associated with advanced, non-cirrhotic fibrosis. METHODS Patients were recruited in the prospectively enrolling European NAFLD Registry. Clinical characteristics and the performance of non-invasive surrogate scores compared with vibration-controlled transient elastography are reported. RESULTS Two hundred and sixty-one patients with non-cirrhotic NAFLD on liver biopsy (mean age 51 ye…

medicine.medical_specialtyCirrhosisType 2 diabetesGastroenterology03 medical and health sciences0302 clinical medicineFibrosisInternal medicineDiabetes mellitusmedicinePharmacology (medical)10. No inequality2. Zero hungerHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologymedicine.disease3. Good health030220 oncology & carcinogenesisLiver biopsy030211 gastroenterology & hepatologybusinessTransient elastographyBody mass indexAlimentary Pharmacology &amp; Therapeutics
researchProduct

Safety and Efficacy of Direct-Acting Antiviral Drugs in Patients with Haemoglobinophaties and Chronic Hepatitis C Infection

2016

Abstract Background and Aim: Direct-acting antiviral drugs (DAAs) have a very high efficacy in patients with hepatitis C virus (HCV) infection, but they have not been extensively used in patients with haemoglobinophaties. To evaluate the safety and efficacy of DAA regimens in this subset we used the ITHACA-SITE dataset, which includes patients with haemoglobinophaties and chronic HCV liver disease treated in Italy. Patients and methods: Between March 2015 and June 2016, 121 patients included in the ITHACA-SITE dataset started DAA regimens. Cirrhosis was defined by FibroScan®showing≥12 kPa performed within 6 months before the treatment. Regimen choice and use of ribavirin were based on viral…

medicine.medical_specialtyCirrhosisbusiness.industryRibavirinHepatitis C virusImmunologyCell BiologyHematologymedicine.diseasemedicine.disease_causeBiochemistryRegimenchemistry.chemical_compoundLiver diseasechemistryDiabetes mellitusInternal medicineImmunologymedicineChelation therapyAdverse effectbusinessBlood
researchProduct

Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice.

2020

Nonalcoholic fatty liver disease (NAFLD) is a clinical condition that encompasses various forms of liver damage not caused by chronic alcohol consumption. In the absence of other etiologies, it ranges from ste- atosis to nonalcoholic steatohepatitis and cirrhosis. The prevalence of NAFLD has considerably increased over the last years owing to the current lifestyle (unhealthy diet and sedentarism). Besides, it is associated with metabolic risk factors such as obesity, arterial hypertension, dyslipidemia, and type 2 diabetes. Given the poor prognosis of patients with advanced NAFLD, a practical therapeutic approach is necessary to halt its natural history. However, no licensed drugs have been…

medicine.medical_specialtyCirrhosisbusiness.industrynutritional and metabolic diseasesDiseaseType 2 diabetesComorbiditymedicine.diseaseObesitydigestive system diseasesArterial hypertension Dyslipidemia Nonalcoholic fatty liver disease Type 2 diabetes Comorbidity Humans Obesity Weight Loss Diabetes Mellitus Type 2 Non-alcoholic Fatty Liver DiseaseDiabetes Mellitus Type 2Weight lossNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseWeight LossInternal MedicinemedicineHumansObesitymedicine.symptomSteatosisbusinessDyslipidemiaPolish archives of internal medicine
researchProduct

Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective s…

2020

Aim HCV infection increases the risk of type 2 diabetes mellitus (T2DM). However, it remains still unclear whether HCV clearance by direct-acting antivirals (DAA) reduces T2DM. Therefore, the effect of HCV eradication on T2DM incidence was assessed. Methods A prospective multicenter case-control study was performed, which included 2,426 HCV patients, 42% of which with liver fibrosis F0-F2 and 58% F3-F4. Study population consisted of a control group including 1099 untreated patients and 1327 cases treated with DAA. T2DM incidence was assessed during a follow-up median period of 30 [IQR: 28-42] months. Risk factors of T2DM were assessed by Cox regression model (Relative risk (RR), Hazard risk…

medicine.medical_specialtyCirrhosisendocrine system diseasesEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineEndocrinologychronic hepatitiInternal medicineInternal MedicinemedicineHumansGlucose homeostasisProspective StudiesProspective cohort studydirect-acting antiviralbusiness.industryIncidenceIncidence (epidemiology)nutritional and metabolic diseasesType 2 Diabetes MellitusHepatitis C Chronicmedicine.diseaseDiabetes Mellitus Type 2Case-Control StudiesRelative riskHCVPopulation studytype 2 diabetesbusinesscirrhositype 2 diabetes.
researchProduct

Changing delta hepatitis patient profile: A single center experience in Valencia region, Spain

2020

Background Delta hepatitis is a rare infection with an aggressive disease course. For almost three decades, however, there have been no epidemiological studies in our traditionally endemic area. Aim To investigate the prevalence of delta hepatitis in a sample of patients with chronic hepatitis B virus (HBV) infection followed at a Hepatology Unit in Valencia, Spain. Methods Retrospective evaluation of anti-hepatitis D virus-immunoglobulin G seroprevalence among patients with chronic HBV infection (n = 605) followed at a reference Hepatology Unit in Spain. Results The prevalence of anti-hepatitis D virus-immunoglobulin G among HBV-infected patients was 11.5%: Male (63%) and median age of 52 …

medicine.medical_specialtyCirrhosismedicine.medical_treatmentImmigrationLiver transplantation03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusEpidemiologymedicineSeroprevalenceViral hepatitisLiver transplantationHepatologybusiness.industryDelta hepatitisCase Control StudyHepatologymedicine.diseaseCirrhosis030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyValenciaViral hepatitisbusinessWorld Journal of Hepatology
researchProduct